{
  "id": 110231,
  "name": "SPARK THERAPEUTICS, INC.",
  "slug": "spark-therapeutics-inc",
  "state": "PA",
  "description": "Biopharmaceutical/gene therapy company",
  "totalSpending": 1400000,
  "filings": 29,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 200000
    },
    {
      "year": 2019,
      "income": 200000
    },
    {
      "year": 2020,
      "income": 200000
    },
    {
      "year": 2021,
      "income": 200000
    },
    {
      "year": 2022,
      "income": 200000
    },
    {
      "year": 2023,
      "income": 200000
    },
    {
      "year": 2024,
      "income": 120000
    },
    {
      "year": 2025,
      "income": 80000
    }
  ],
  "firms": [
    "BROWNSTEIN HYATT FARBER SCHRECK, LLP"
  ],
  "lobbyists": [
    "ALFRED MOTTUR",
    "CATE BLANKENBURG",
    "BRIAN MCKEON",
    "ARACELI GUTIERREZ",
    "LAURA BOLLIER",
    "NADEAM ELSHAMI",
    "JEROME MURRAY",
    "EMILY FELDER",
    "SOHIL KHURANA",
    "DEEMA TARAZI",
    "ADAM STEINMETZ",
    "DAVID REID",
    "GREGORY SUNSTRUM"
  ],
  "issues": [
    "HCR",
    "MED",
    null
  ],
  "sampleDescriptions": [
    "Issues related to the development of therapies for rare diseases",
    "Issues related to the development of therapies for rare diseases \nPatient Affordability Value and Efficiency Act",
    "Issues related to the development of therapies for rare diseases                                             Patient Affordability Value and Efficiency Act",
    "Issues related to the development of gene therapies for rare diseases",
    "Issues related to the development of gene therapies for rare diseases S. 4204/ H.R. 2666 MVP ACT"
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": -60,
  "trajectory": "declining",
  "yearsActive": 8,
  "avgAnnualSpending": 175000,
  "peakYear": 2018,
  "lobbyistCount": 13,
  "firmCount": 1,
  "issueCount": 2
}